NCT04205838 2026-02-27
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
Clinical Trials
7 trialsNCT03422393 2024-07-05
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
University of California, San Diego
Phase 1 Active not recruiting
NCT04029038 2023-08-21
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT04149821 2023-06-15
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03222024 2020-10-28
SIS
West China Hospital
Completed
NCT03525665 2020-02-06
Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression
Fondazione Italiana Linfomi - ETS
Completed
NCT00530140 2011-10-06
FLIDVAX2006
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Unknown